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Abstract The aim of this study was
to compare MRI of the breast with
18F-fluoro-deoxy-glucose (FDG)
positron emission tomography (PET)
in patients with suspected local or
regional breast cancer recurrence or
suspected contralateral breast cancer.
Thirty-two patients (mean age
57.2 years, age range 32–76 years)
with suspected loco-regional recur-
rence (n=19), chest wall recurrence
(n=5), and suspected secondary 
tumor of the contralateral breast
(n=8) underwent MRI of the breast
and FDG PET of the whole body and
breast region. Cytology/histology
(n=17) or a clinical follow-up exami-
nation (n=15) with additional imag-
ing served as the standard of refer-
ence. A McNemar test was per-
formed to compare PET and MRI,
and kappa was determined to 
quantify agreement of both methods.
Sensitivity was 79 and 100%, speci-
ficity was 94 and 72%, and accuracy
was 88 and 84% for MRI and PET,
respectively. Additional metastases
outside the field of view of MRI
were found in PET in 5 patients. In
this study both imaging methods had
comparable accuracy. The detection
of distant metastases with whole-
body PET imaging can influence 
patient management.
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Introduction
Imaging is an important part in the management of
breast cancer patients and is used for the detection and
staging of a primary tumor as well as the evaluation of
patients with suspected recurrence. Positron emission to-
mography (PET) with 18F-fluoro-deoxy-glucose (FDG)
can help to visualize a primary lesion in the breast and
can differentiate benign from malignant breast patholo-
gies [1]. Furthermore, multifocality of lesions can be de-
tected and PET has been proven accurate in identifying
regional lymph node involvement of the axillary, supra-
clavicular, and internal mammary lymph nodes [2, 3].
The PET provides a whole-body staging and can detect
involvement of mediastinal lymph nodes and distant me-
tastases [3, 4].
According to the recommendations of the European
Society for Medical Oncology (http://www.esmo.org/
ESMO minimum clinical recommendations for diagnosis,
adjuvant treatment and follow-up of primary breast can-
cer), patients with breast cancer should be examined clin-
ically every 3–6 months for 3 years, every 6–12 months
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for 2 years, and then annually. In addition, breast cancer
patients should undergo ipsilateral (after breast-conserv-
ing surgery) and contralateral mammography every
1–2 years to check for local recurrence or a second con-
tralateral cancer. Additional imaging methods, such as
chest X-ray, CT scans of the chest or abdomen, and bone
scans, are not routinely recommended for asymptomatic
patients. Accordingly, FDG PET is not recommended for
routine follow-up studies, but it has been shown that FDG
PET is useful for whole-body restaging in patients with
suspected recurrence [5]. If recurrent disease is suspected
on the basis of clinical or mammographic findings, ultra-
sound with fine-needle aspiration (FNA) or stereotactic
biopsy under mammographic guidance is performed as
the next step. Evaluation of patients with post-treatment
changes due to surgery and radiation therapy is some-
times difficult. Post-treatment follow-up is a challenge in
women after breast-conserving therapy, because tissue
changes can mimic or obscure recurrent disease. Magnet-
ic resonance imaging of the breast can be used as a prob-
lem-solving tool in the evaluation of these patients in
whom equivocal changes are identified at mammography
or physical examination [6]. Contrast-enhanced MRI has
shown to be highly effective in identifying recurrent 
tumor, but false-positive cases, mostly due to post-thera-
peutic or inflammatory changes, may occur [7, 8, 9, 10,
11, 12, 13]. In a recent study a direct comparison between
MRI and FDG PET was performed in women with suspi-
cious breast lesions [3]. Both methods had the drawback
of false-positive results, but PET was able to detect occult
lymph node involvement and distant metastases not
found with conventional staging methods such as skeletal
scintigraphy, chest X-ray, and liver ultrasound [3].
The aim of this study was to compare FDG PET and
MRI in the follow-up of patients with breast cancer.
Materials and methods
Patients
Between May 2000 and May 2001, 49 women were included pro-
spectively and examined with FDG PET. All patients had a history
of breast cancer and were scheduled for MR imaging due to sus-
pected recurrent disease or a suspected second tumor in the con-
tralateral breast. The study had been approved by the Institutional
Review Board and written informed consent was obtained in all
cases.
Thirty-two of 49 patients were available for comparison with
MRI (age range 32–76 years, mean age 57.2±10.2 years). Of the
other 17 patients, 3 patients were lost to follow-up and in 9 pa-
tients a standard of reference could not be obtained. In the remain-
ing 5 patients, MRI was not available for comparison with PET,
because it was non-diagnostic due to severe motion artifacts
(n=1), incomplete due to claustrophobia (n=1), or the interval be-
tween the MRI and PET exceeded the time interval of 4 weeks,
which had been defined as being still acceptable for our study
(n=3).
All patients included in the comparative study had been previ-
ously treated for breast cancer with surgery (100%), radiation ther-
apy (44%), and chemotherapy (38%; Table 1). Mastectomy was
performed in 11 patients (bilaterally in patients 7 and 23 and uni-
laterally in patients 4, 6, 13, 15, 20, 21, 22, 24, 32). Initial diagno-
sis and treatment of breast cancer was made 8–260 months prior 
to PET and MR scans (median 32.5 months, mean 51.9 months;
Table 1). Nineteen of 32 women (60%) had equivocal clinical or
mammographic findings of the ipsilateral side and thus suspected
loco-regional recurrence could not be excluded (mean 58.6 years;
Table 1). Five of 32 patients (16%) had suspected chest wall recur-
rence ipsilateral to the initial disease (mean 58.6 years; Table 1).
Eight of 32 (25%) women had suspicious findings in the contralat-
eral breast (mean 53.0 years; Table 1). In 22 women a lesion in the
breast, thoracic soft tissues, or regional lymph node stations was
palpable. In 4 women no lesion was palpable (patients 4, 11, 17,
21) and in 6 patients this information was not available (patients 5,
12, 19, 28, 30, 31). Lesion size was ≥10 mm in 27 patients and
<10 mm in 4 (patients 4, 5, 6, 17). Lesion size was not document-
ed in patient 31.
Standard of reference
Cytology or histology was used as a standard of reference. If not
available, patients with negative findings in MRI and/or negative
PET findings underwent a follow-up examination after at least
12 months using additional imaging such as mammography
with/without ultrasound and clinical evaluation (Table 2). In pa-
tients with suspected local or regional pathology, but without his-
tological or cytological proof, further imaging methods were used
to verify suspected loco-regional disease and distant metastases
(Table 2). For the evaluation of local thoracic wall invasion CT
scanning and/or bone scintigraphy was added. All available imag-
ing studies, including mammography, ultrasound, CT, MRI, and
PET, were read in consensus and the results were discussed with
the gynecologist who had clinically examined the patient. This
served to establish the reference standard for loco-regional disease
and served for the decision to start a treatment.
Data acquisition
The PET scanning was done as follows: all patients fasted for at
least 4 h prior to the PET scan. Approximately 45 min before im-
age acquisition, the patients received an intravenous injection of
386 MBq (±83 MBq) FDG. Images were acquired on a GE 
Advance PET scanner (GE Medical Systems, Waukesha, Wis.) in
2D mode with an axial field of view (FOV) of 14.6 cm. Emission
scans were acquired with 4 min per FOV and overlap of one slice
(4.25 mm) at the borders. Women scanned for suspected loco-
regional recurrence and contralateral breast cancer were placed in
the PET scanner in a prone position and a PET scan localized on
the breast fields using two axial FOV were acquired. For patient
positioning we used an MRI breast coil support from which the
actual receiver coil had been removed. This permitted to come as
close as possible to the MR imaging position. Attenuation correc-
tion was obtained for these two FOV using the built-in 68Ge sourc-
es of the scanner. After this PET acquisition, patients were placed
supinely, and a scan from the pelvic floor to the head was per-
formed. This whole-body scan was acquired to evaluate the patient
with regard to distant metastases and was obtained without attenu-
ation correction to save time. In the 5 women (patients 20–24; 
Table 2) who had had surgical ablation of one or both breasts, and
who had a suspected recurrence in the thoracic wall, both studies,
PET and MRI, were performed in supine position only. In these
patients, PET scans without attenuation correction covering the
whole body from the head to the pelvic floor were acquired.
An MRI scan of the breast was obtained in prone position on 
a 1.5-T scanner (Signa CV/I or Horizon, GE Medical Systems,
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Milwaukee, Wis.) using a bilateral breast surface coil. A T1-
weighted 3D FSPGR sequence with the following parameters was
used for image acquisition: TR 7.7 ms; TE 1.8 ms; flip angle 30°;
matrix 252¥192; field of view (FOV) 30¥30 cm; slice thickness
3 mm without gap; and the frequency-encoding direction was an-
teroposterior. After a localizer scan, precontrast and four dynamic
post-contrast (0.1 mmol/kg body weight; Gd-DTPA, Magnevist,
Schering, Berlin, Germany) image series (0.5, 1, 3, 8 min) were
obtained. The short echo time was chosen to save imaging time.
The use of this imaging protocol has the possible drawback of 
opposed-phase effects leading to a reduction of the MR signal 
because an intra-voxel phase shift cannot be excluded; however,
regarding the time course of a Gd-DTPA-induced signal change,
this effect was considered to be not relevant. All enhanced images
of the first and last contrast-enhanced series were processed by
subtracting the corresponding precontrast scan images. In patients
with breast implants due to reconstructive surgery, additional axial
and sagittal T2-weighted fast spin-echo images were acquired 
to assess implant integrity. In women who had undergone ablative
surgery of one or both breasts, MRI was acquired with the same
imaging protocol as described above and additional fat-saturated
T2-weighted fast spin-echo and contrast-enhanced T1-weighted
spin-echo sequences to evaluate the thoracic wall and also the
contralateral breast. In cases of bilateral ablation an MR imaging
protocol using the torso coil with axial, sagittal T1-weighted 
spin-echo images, T2-weighted fast spin-echo, and contrast-
enhanced T1-weighted fat saturated spin-echo sequences were 
acquired.
Image analysis
All emission images were corrected for scatter and attenuation
correction of the breast images (two fields of view) were done 
using segmented transmission data, i.e., predefined values for
bone, tissue, and lung were assigned to the corresponding areas
and smoothed with the same filters as the emission data to reduce
statistical noise in the images of these short transmission scans
[14, 15]. The PET images were reconstructed with GEMS soft-
ware release 4.1 using an iterative OSEM algorithm implemented
on the PET camera for routine clinical use (2 iterative steps, 
28 subsets, zoom of 1.0, 128¥128 image matrix, voxel size
4.39¥4.39¥4.25 mm). For the whole-body scan filtered back pro-
jection was performed without attenuation correction.
The PET images were viewed in the three orthogonal imaging
planes as well as by using cine mode on a digital viewing system
(GE View, Dornstadt, Germany). Lesions were defined by in-
creased uptake of FDG and compared with physiologic activity in
the heart and brain. If a lesion was present within the two FOV
over the breast, the same lesion was identified also in the whole-
body scan to allow direct comparison with physiologic uptake in
the brain. Intensity assessment of a lesion was thus performed 
using a scale between 1 (lung uptake) and 4 (brain uptake). This
allowed semi-quantitative evaluation of FDG uptake into the le-
sions. Lesions with uptake comparable to the brain (uptake inten-
sity 4) or more than normal liver uptake (uptake intensity 3) were
considered to be malignant. Lesions with uptake intensity 1 (lung
uptake) and 2 (normal liver uptake) were considered to be not ma-
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Table 1 Patient characteristics Patient Indication for Time since Previous Previous Radiation 
no. PET and MRI first treatment chemotherapy radiotherapy treatment stopped
(months) (months ago)
1 Local recurrence 13 No Yes 11
2 Local recurrence 45 No Yes >18
3 Local recurrence 17 Yes No
4 Local recurrence 232 No No
5 Local recurrence 8 Yes No
6 Local recurrence 149 No No
7 Local recurrence 33 No No
8 Local recurrence 12 No Yes 10
9 Local recurrence 44 No Yes >18
10 Local recurrence 14 No No
11 Local recurrence 30 Yes Yes >18
12 Local recurrence 23 No Yes >18
13 Local recurrence 64 No No
14 Local recurrence 18 No No
15 Local recurrence 42 Yes Yes 12
16 Local recurrence 23 No Yes >18
17 Local recurrence 19 No No
18 Local recurrence 45 No No
19 Local recurrence 33 Yes Yes >18
20 Thoracic wall 260 Yes Yes >18
21 Thoracic wall 70 No Yes >18
22 Thoracic wall 22 Yes Yes >18
23 Thoracic wall 47 No No
24 Thoracic wall 32 Yes No
25 Contralateral 70 Yes No
26 Contralateral 20 Yes No
27 Contralateral 16 No No
28 Contralateral 73 No No
29 Contralateral 30 Yes Yes >18
30 Contralateral 69 No No
31 Contralateral 19 Yes Yes >18
32 Contralateral 70 No No
The three patient subpopula-
tions, i.e., women with sus-
pected ipsilateral recurrence,
women with suspected thoracic
wall recurrence, and women
with suspected contralateral
breast cancer, are listed to-
gether. In all patients receiving
chemotherapy, the treatment
was stopped several months 
before this study. Three 
patients underwent radiation
treatment less than 18 months
before the MRI and PET scans
were acquired. This could dis-
turb interpretation of lesions in
an MRI scan, but was not a
problem in the patients of this
study
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Table 2 Results of the imaging tests and the standard of refer-
ence. The reference standard and the definitive findings of PET
and MRI scans are listed. Only lesions in the field of view of PET
and MRI were used for statistical comparison. M mammography;
CT computed tomography; US ultrasound; BP infiltration=infiltra-
tion of the brachial plexus; LN lymph node; TP true positive; 
TN true negative; FP false positive; FN false negative; DM distant
metastases
Patient Standard of reference Follow-up PET MRI Reason for MRI and PET PET and MRI findings
no. after PET 
and MRI 
(months)
1 Negative Follow-up (M, US) 12 FP TN Ipsilateral (10¥8 mm) and Normal ipsi- and contralateral
contralateral nodule on (fibroadenoma) findings and 
mammography, palpable normal lymph node on MRI, 
axillary lymph node suspected secondary cancer 
on PET
2 Negative Histology (surgery) TN TN Palpable lesion approximately Scar on MRI, on PET uptake 
50 mm not increased (Fig. 2)
3 Positive Therapy TP, DM TP Painful diffuse induration On MRI and PET recurrence 
(bone metastases) of breast (Fig. 1)
4 Negative Follow-up (M) 14 TN TN Nodule within the scar On MRI granuloma, on PET 
(approximately 6 mm) uptake not increased
5 Negative Follow-up (M, US) 14 TN TN Nodule on mammography, 5¥7 mm benign on MRI, 
solid on US on PET uptake not increased
6 Negative Follow-up (M) 15 TN TN Palpable induration in scar 6¥7 mm postoperative 
granuloma on MRI, on PET 
uptake not increased
7 Negative Histology (surgery) TN TN Painful induration with fistula Fistula and lymph node 
and palpable lymph node and (13 mm) on PET and MRI 
additional adjacent solid visible, fistula 3¥23 mm 
lesion on US (12¥7 mm) (pathology specimen), 
no additional lesion
8 Negative Follow-up (M) 12 TN TN Diffuse induration on On MRI posttherapy changes 
mammography fibrocystic and two lymph nodes up to 
changes, palpable axillary 10 mm, on PET uptake not 
lymph nodes increased
9 Negative Follow-up 16 FP TN Lesion on mammography On MRI changes after radiation 
(M, US, CT) adjacent to the thoracic wall treatment (9¥12 mm), on PET 
increased FDG uptake
10 Positive Follow-up (M, US) 12 TP FN Diffuse induration in breast Considered to be an 
and dense tissue on inflammation on MRI 
mammography, palpable (several centimeters), 
nodules axillary and suspected multifocal recurrence 
supraclavicular on PET
(5¥7mm on US)
11 Negative Histology (biopsy) FP TN Nodule (not palpable) On MRI scar, suspected local 
and calcifications on recurrence on PET (pathology 
mammography specimen: 8¥10 mm fibrotic 
nodule with calcifications in 
scar tissue)
12 Negative Follow-up (M) 20 TN TN 10 mm lesion on Fibroadenoma on MRI, on PET
mammography uptake not increased
13 Positive Histology (surgery) TP FN Palpable nodule within the On MRI inflammation reaction
scar, solid lesion on US and fibrotic nodule 9¥14 mm, on
PET suspected local recurrence
14 Negative Histology (surgery) FP TN On mammography dense l On MRI posttherapeutic 
esion 14¥13 mm, palpable changes (pathology specimen 
with inflammation), on PET 
suspected recurrence
15 Positive Cytology TP TP On mammography two On MRI and on PET suspected 
nodules 4¥5 and 9¥12mm local recurrence (on PET 1 
nodule detected)
16 Positive Histology (biopsy) TP TP Palpable axillary lymph node On MRI and PET suspected 
and scar, on US supected axillary lymph node and 
lesion recurrence adjacent to a rib 
(14¥15 mm)
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17 Negative Follow-up (M) 12 TN TN Suspect nodule on On MRI posttherapeutic 
mammography and US changes, on PET uptake not 
(4¥5 mm) increased
18 Positive Histology (surgery) TP TP On mammography “diffuse On MRI two nodular lesions, 
transparency decrease” on PET one lesion in the breast 
(size N/A) (pathology specimen two 
lesions 10 and 12 mm in the 
same breast)
19 Positive Histology (biopsy) TP TP On mammography nodule On MRI and PET recurrence
12¥11 mm in the scar
20 Positive Histology (surgery) TP TP Palpable nodule at thoracic On MRI lesion at thoracic wall 
wall adjacent to the scar adjacent to the scar and second 
lesion infraclavicular, on PET 
increased uptake in two lesions 
(pathology specimen 11 and 
15 mm)
21 Positive Cytology TP TP Local pain at thoracic wall On MRI soft tissue invasion of 
and clinical signs of brachial tumor to the brachial plexus 
plexus infiltration, US dense with nodules 8 and 13 mm, on 
lesion PET diffuse uptake
22 Positive Therapy TP, DM TP Painful palpable induration Lesion 13¥7 mm with 
(bone metastases) adjacent to scar infiltration of rib on MRI, 
on PET visible lesion and 
DM
23 Positive Therapy TP TP Parasternal palpable nodule Lesion on MRI (20¥25 mm) 
(loco-regional LN and PET
and soft tissues)
24 Positive Cytology, therapy TP TP Nodules supraclavicular, On MRI several lymph nodes 
(BP infiltration) infraclavicular and axillary and lesion 12¥25 mm at 
with clinical signs of brachial brachial plexus, on PET all 
plexus infiltration lesions visible
25 Positive Cytology, therapy TP FN Palpable nodule in scar On MRI suspected granuloma 
(loco-regional LN 11¥9 mm and inflammation, 
and soft tissues) on PET positive
26 Negative Histology (surgery) FP FP Palpable axillary lymph nodes On MRI suspect lesion in breast 
and on mammography tissue 8¥14 mm and two lymph 
star-like lesion nodes (not malignant) 20 mm 
each, on PET increased uptake 
in all lesions
27 Negative Cytology, therapy TN, DM TN Lesion on mammography On MRI and on PET breast 
(bone metastases) (15 mm) on US dense normal, only additional finding 
on PET (local lesion in cytology 
fibrotic tissue)
28 Positive Therapy TP, DM TP On mammography fibrocystic On MRI lesion 25¥17 mm and 
(bone metastases) disease and palpable axillary lymph node, on PET lesion 
lymph node visible and distant metastases
29 Negative Follow-up (M) 15 TN TN A palpable lesion (11 mm on On MRI fibroadenomas, on PET 
mammography) and a second not visible
nodule 4¥5mm on 
mammography
30 Negative Follow-up (M) 12 TN TN Lesion on mammography On MRI scar, on PET uptake 
13 mm not increased
31 Negative Cytology, therapy TN, DM TN Fibrocystic disease on Fibrocystic disease on MRI, no 
(bone metastases) mammography with star-like malignant lesion, on PET 
lesion (size N/A) normal breast and DM
32 Negative Histology (surgery) TN TN On mammography two lesions On MRI no signs of 
15¥10 and 12¥16 mm malignancy, fibrocystic disease, 
on PET uptake not increased
Table 2 (continued)
Patient Standard of reference Follow-up PET MRI Reason for MRI and PET PET and MRI findings
no. after PET 
and MRI 
(months)
lignant, e.g., inflammation or posttherapeutic changes. Standard-
ized uptake values were not routinely calculated for these patients,
because iteratively reconstructed images were assessed and be-
cause the way of visual evaluation aimed at high sensitivity. The
PET scans were read in consensus by two experienced nuclear
medicine physicians (H.C.S. and G.W.G.) who were blinded for
the results of the MR scans as well as other clinical and imaging
information. After the decision had been made if a finding visible
in the PET scan of the breast was benign or malignant, the PET
scans were directly compared with the MR scans. This was done
to identify if the lesion was located outside of the FOV of the MR
scan, because the position of the patients’ breast in the MRI could
still be different from the position in PET.
In MRI, a semi-quantitative analysis of the signal intensity vs
time curve was performed in lesions with early contrast enhance-
ment as previously described [16]. A >50% relative increase of
signal intensity after contrast injection on early subtraction imag-
es was considered to be a sign for malignancy [16]. The MR im-
ages were documented on film, and image interpretation was per-
formed in consensus by two experienced radiologists (A.H.K. and
R.K-H.) blinded to clinical information and results of the PET
scans.
Statistical evaluation
Lesions visible in the PET image and in the MR image were taken
for statistical comparison. Lesions only visible in PET, i.e., in 
areas outside the FOV of the MR scan, were considered to be 
additional information of the PET scan and were not used for sta-
tistical comparison of both imaging methods. The values for sensi-
tivity, specificity, positive and negative predictive value, and accu-
racy were determined. Furthermore, a McNemar test was per-
formed to compare PET and MRI (significance level of p=0.20 for
equal effects), and kappa was determined to quantify agreement of
both methods.
Results
Cytology (n=6), biopsy (n=3), or histology after surgical
intervention (n=8) was available as a standard of reference
in 17 of 32 patients (53%; Table 2). The FNA was positive
in 4 patients, negative in 2 patients, and not conclusive in
1 patient (patient 5; Table 2). In patient 10 FNA of a su-
praclavicular lymph node, but not of the breast itself, was
done, showing inflammation reaction. This patient and pa-
tient 23 rejected further investigation of the local findings
using FNA. In the other patients (ultrasound-guided) FNA
of the suspected lesion was not done either because biopsy
or surgical intervention was planned or because the patient
preferred to undergo MRI prior to a more invasive proce-
dure. In 9 women histology/cytology was positive for re-
currence (28%) and in 8 women negative (25%; Table 2).
In the women with negative pathologic findings and no
evidence of distant metastases (patients 2, 7, 11, 14, 26,
32) a routine follow-up examination after 1 year with
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Fig. 1a, b Magnetic resonance imaging and fluoro-deoxy-glucose
(FDG) positron emission tomography (PET) images of a 33-year-
old woman (patient 3) with clinically suspected local recurrence. 
a Transverse early subtraction MR images (first contrast-enhanced
image–precontrast image) illustrate early enhancement in the re-
current cancer (R) and in a lymph node (LN). b Sagittal and trans-
verse PET images illustrating increased FDG uptake in the same
lesions of recurrent cancer (R). An additional lymph node metasta-
sis in the retroclavicular region, outside the field of view (FOV) of
MRI, is seen only in PET (LNoutside)
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Fig. 2a–d Mammography, MRI, and FDG PET images of a 
63-year-old woman (patient 2) with a suspected local recurrence
in a routine mammography 45 months after the end of treatment. 
a Mammography of the right (R) and left (L) breast in a lateral
view. There is postoperative deterioration of the soft tissues with
metallic clips (p). At the site of surgery the tissue is less radiolu-
cent (p). Egg-shell calcifications probably due to a cystic lesion
are present (c). b Transverse T1-weighted gradient-echo MRI 
images showing the identical slice over time with late enhance-
ment of gadolinium contrast in a benign lesion of the right breast
(arrow). c Transverse subtraction images of the same breast. The
early (upper image; first contrast-enhanced image/precontrast im-
age) and late (lower image; last contrast-enhanced image/precon-
trast image) images illustrate late enhancement of gadolinium con-
trast. This is suggestive of a benign lesion (arrows). d Two con-
secutive transverse PET images. There is only low FDG uptake
within the scar, which is not suspicious for a local recurrence 
(arrows). Since the patient felt a hard nodule growing at this site,
surgery was performed revealing fibrosis with calcifications
mammography with/without ultrasound was available
without evidence of disease. In the 9 women with positive
local findings in cytology/histology (patients 13, 15, 16,
18, 19, 20, 21, 24, 25) a treatment of the local or regional
recurrence was started.
In 11 of 32 patients (patients 1, 4, 5, 6, 8, 9, 10, 12,
17, 29, 30) a mean follow-up of 14 months (range
12–20 months) with an additional clinical examination
and imaging served as the reference standard (Table 2).
Mammography with/without ultrasound was performed
if no lesion was suspected in MRI and PET. If a lesion
was suspected in PET or MRI, one or more additional
imaging examinations (mammography, ultrasound, CT
of the chest) were performed together with clinical 
examination (Table 2). Only 1 of these 11 patients had a
local recurrence (patient 10).
The 5 patients with distant metastases (patients 3, 22,
27, 28, 31) underwent bone scintigraphy, CT or abdomi-
nal ultrasound and treatment with chemotherapy or 
bisphosphonates was started (Table 2). Two of these 
5 patients (patients 27, 31) receiving therapy for distant
bone metastases had no evidence of loco-regional recur-
rence with MRI and PET (both considered true negative;
Table 2). Examples of true-negative and true-positive
MRI and PET findings are given in Figs. 1 and 2. 
The PET was true positive in 14 women (44%), 
true negative in 13 women (41%), and false-positive in 
5 women (16%). There were no false-negative PET find-
ings. The MRI was true positive in 11 women (34%), true
negative in 17 women (53%), false negative in 3 women
(9%), and false positive in 1 woman. Findings of PET and
MRI vs the standard of reference split for the different pa-
tient subgroups are listed in Table 2. The values for sensi-
tivity, specificity, positive and negative predictive value,
and accuracy are listed in Table 3. The PET had a higher
sensitivity than MRI but a lower specificity. The results of
the McNemar tests revealed no significant difference be-
tween the sensitivity of PET and MRI (p=0.25) and be-
tween the specificity of PET and MRI (p=0.25). In this
study, both imaging methods MRI and PET had compara-
ble accuracy (p=1.0); however, the kappa coefficient be-
tween PET and MRI was 0.58±0.13 indicating that both
imaging tests could complement one another.
Discussion
Because mammography is less specific after breast sur-
gery, the addition of sonography or MRI in women with
breast cancer is useful for the evaluation of suspicious
findings in the breasts and regional lymph nodes. While
MRI is an established imaging method in suspected re-
currence, only a few studies have been published show-
ing a role of FDG PET in this situation. In a study by
Bender et al. [5], PET detected significantly more often
lymph node metastases in patients with suspected local
recurrence than CT or MRI.
In the 19 patients in our study scanned for suspected
loco-regional recurrence, 4 false-positive PET examina-
tions were obtained, 1 of them showing contralateral up-
take, which was thought to be a second tumor. In these
patients who underwent mammography and clinical con-
trol of both breasts, the likelihood to detect a new contra-
lateral cancer in a breast considered to be normal when
using other imaging examinations is probably low, since
increased FDG uptake can also be found in benign le-
sions such as fibroadenoma [17]. Three false-positive
PET findings were due to suspected lymph node or 
thoracic wall involvement. In 2 patients false-positive
PET scans were confirmed to be negative by histology
(patients 11 and 14). These patients had scar tissue with
calcifications (patient 11) and non-specific inflammation
(patient 14), respectively. The high rate of false-positive
findings of PET is a well-known problem, since FDG is
also taken up in inflammatory tissue [3, 18]. In this study
no false-negative PET scans were found due to the 
highly sensitive way of visual image interpretation. In
contrast, Moon et al. report a sensitivity and a specificity
of FDG PET of 93 and 79% with a positive and negative
predictive value of 82 and 92% for the detection of 
recurrence and metastases [19]. Using MRI we had 3
false-negative findings and 1 false-positive finding;
hence, MRI had better specificity but lower sensitivity
than FDG PET in this evaluation.
Whole-body PET identified additional metastases 
lying outside the FOV of the MR image in 5 patients
(16%), but only 3 also had a loco-regional lesion. In the
other 2 patients a loco-regional problem was excluded.
This finding was explained by the patient reporting pain at
the anterior or lateral thoracic wall, which was in fact
caused by vertebral or rib metastases not being visible in
MRI with a limited FOV. In addition, we found that 
detection of supraclavicular lymph node metastases can be
difficult, since in MR this region may be at the border or
even outside of the FOV in tall women (Fig. 1). This re-
gion corresponds to the next level of possible lymph node
involvement after resection of axillary lymph nodes. All
women with distant metastases also had bone metastases,
which were visible in the PET scans. It has been reported
that osteolytic lesions show higher FDG uptake than os-
teoblastic lesions [20]. In the same patients we also found
distant metastases in the liver or lung, which confirmed
previous reports, underlining that whole-body FDG PET
is a suitable restaging tool in breast cancer patients [3].
The capability of FDG PET to detect bone metastases at
an early time point may be important, since appropriate
therapy using bisphosphonates combined with cytotoxic
or hormonal treatment can prevent both, the development
of further bone metastases and pathological fractures [21].
Both PET and MRI were true positive in all 5 patients
with local recurrence of the thoracic wall as verified us-
ing cytology/histology, CT, or bone scintigraphy. These
patients had previously undergone mastectomy and,
therefore, had FDG whole-body PET in supine position;
however, the small number of patients in this study pre-
cludes to claim that PET and MRI are equally useful in
these patients. In a study involving breast cancer patients
with brachial plexopathy, Ahmad et al. [22] showed that
FDG PET was able to identify 14 of 19 patients with pain
and suspected recurrence, whereas CT was inconclusive
or negative in 6 patients; therefore, further studies have to
evaluate if FDG PET is useful in this patient group and if
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Table 3 Comparison of the imaging tests
MRI PET
Sensitivity (%) 79 100
Specificity (%) 94 72
Positive predictive value (%) 92 74
Negative predictive value (%) 85 100
Accuracy (%) 88 84
it can provide additional information compared with
MRI, e.g., for the planning of a radiation treatment.
Forty-four percent of our patients received radiation
treatment after surgery. Three patients (patients 1, 8, 15)
had their radiation treatment stopped less than 18 months
prior to the acquisition of MRI and PET scans (Table 1).
This is important, because up to 18 months after radia-
tion treatment, interpretation of MRI can be difficult.
Post-therapeutic inflammatory reactions can influence
MR images leading to false-positive interpretation [23].
Also in PET, a radiation-induced inflammatory reaction
may influence image interpretation. Based on observa-
tions in patients with head and neck cancer, it can be
suggested that such an influence on PET imaging will
not last for 18 months, but merely for several weeks
[24]; however, in this study 1 true-negative and 1 true-
positive PET and MR scan were found and the false-
positive PET scan in patient 1 was due to over-interpre-
tation of a finding in the contralateral normal breast,
which received no radiation treatment.
Eight patients were included in this study with an
equivocal or suspicious finding in the contralateral
breast. Fifty percent of these women had undergone pre-
vious chemotherapy (patients 25, 26, 29, 32). This treat-
ment was stopped several months before the PET and
MRI examination and the false-positive findings of PET
and MRI in patient 26 and the false-negative MR scan in
patient 25 cannot be explained by a treatment effect. In
one of these women (patient 26) MRI and PET found a
lesion suspicious for recurrence, which turned out to be
inflammation tissue on histology.
In some patients we found it difficult to correctly iden-
tify the corresponding lesions in MRI and PET, since the
patients’ breasts did not always have exactly the same po-
sition during the two imaging sessions. For MRI, the
breasts are placed in a dedicated surface coil which may
compress the breast in a mediolateral way to avoid motion
blurring [8]. Although PET imaging was performed in an
identical position using an MRI breast coil holder with re-
moved coil, we found that the breasts’ position was differ-
ent in some patients. This effect was more evident in
women with large breasts, which seemed to be more com-
pressed during MRI. We found also that co-registration of
MRI and PET images of the breasts was not helpful.
There were several limitations to our study. The num-
ber of included patients is small and it might thus be to
early to draw a definitive conclusion from our results.
An additional limitation is that cytological/histological
proof was only available in 53% of patients, whereas in
the other patients a combination of additional imaging
studies and clinical evaluation during a 12- to 20-month
follow-up served as the standard of reference.
Regarding the low value of kappa between PET and
MRI, a combination of both methods could in principle
improve patient management. In 4 false-positive PET
scans MRI was clearly normal. In contrast, in two of
three false-negative MRI scans a non-specific inflamma-
tion reaction was suspected in MRI, whereas PET was
correctly positive. If in all patients both examinations
would be performed routinely, and only findings would
be accepted which are positive in both examinations, 
the specificity would increase at the cost of a lower sensi-
tivity. Using PET as an initial imaging method and MRI
as backup in cases of suspicious PET findings could be
an interesting approach: in the case of a positive PET
scan, a positive MRI could guide histological confirma-
tion and a negative MRI could result in a wait-and-watch
strategy. Using this approach, only patient 13 would be
false negative and patient 26 false positive. Sensitivity
and specificity of the combined imaging approach would
then become 93 and 94% with an accuracy of 94%.
Conclusion
In conclusion, these preliminary data suggest that PET and
MRI are comparable in imaging patients with suspected
breast cancer recurrence; however, these imaging methods
should be reserved for selected cases with non-conclusive
mammographic or sonographic findings. Although a com-
bination of MRI and PET seems interesting from an aca-
demic point of view, such an approach would not be justi-
fied in a routine clinical setting due to the high cost.
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